Genetic engineering of IgG-glucuronidase fusion proteins
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
beta-Glucuronidase (GUSB) is a lysosomal enzyme that could be developed as a brain therapy for Type VII Mucopolysaccharidosis. However, GUSB does not cross the blood-brain barrier (BBB). To enable BBB transport of the enzyme, human GUSB was re-engineered as a fusion protein with the chimeric monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb crosses the BBB on the endogenous insulin receptor, and acts as a molecular Trojan horse to ferry into brain the GUSB. The 611 amino acid GUSB was fused to either the carboxyl or amino terminus of the heavy chain of the HIRMAb. This study illustrates the differential retention of functionality of IgG-enzyme fusion proteins depending on how the fusion protein is engineered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interactions of IGF-1 with the Blood-Brain Barrier in vivo and in situ
Pan, W., & Kastin, A. J. (2000) · Neuroendocrinology · doi:10.1159/000054584 · Cited by 185
Cited by
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Pardridge, W. M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.952627 · Cited by 152
Self-citationDelivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152
“Fusion of a lysosomal enzyme, beta-glucuronidase (GUSB), to the N-terminus of the heavy chain of the HIRMAb resulted in a[ 95% loss of HIRMAb affinity for binding to the HIR [83].”
BackgroundSelf-citationCalias, P., Papisov, M., Pan, J., Savioli, N., Belov, V., Huang, Y., Lotterhand, J., Alessandrini, M., Liu, N., Fischman, A. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030341 · Cited by 133
“These have included fusion proteins that target delivery by transcytosis using insulin [5], [6], or transferrin [7], [8], receptors.”
Background
Metadata
- Authors
- Boado, R. J., & Pardridge, W. M.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2009-10-14
- Volume
- 18
- Issue
- 3
- Pages
- 205-211
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2014004221
- Cited by
- 37
- References
- 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic engineering of IgG-glucuronidase fusion proteins. https://app.cochat.ai/papers/10.3109/10611860903353362
- The paper
- Boado, R. J., & Pardridge, W. M. (2010). Genetic engineering of IgG-glucuronidase fusion proteins. Journal of Drug Targeting. https://doi.org/10.3109/10611860903353362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.